http://www.advfn.com/nasdaq/rss.asp?symbol=SGEN Seattle Genetics Company Newsfeed en Tue, 23 Oct 2012 09:55:29 EDT Tue, 23 Oct 2012 09:55:29 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=54654458&headline=abbott-to-pay-25-million-fee-to-expand-cancer-technology-rights http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=54654458&headline=abbott-to-pay-25-million-fee-to-expand-cancer-technology-rights <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Abbott Laboratories (ABT) will pay a $25 million upfront fee to Seattle Genetics Inc. (SGEN) for expanded rights to utilize Seattle Genetics' technology for cancer. </p> <p> The expanded collaboration between the two drug companies allows Abbott... Tue, 23 Oct 2012 09:55:29 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=50744698&headline=fda-warns-on-serious-brain-infection-risk-with-lymphoma-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=50744698&headline=fda-warns-on-serious-brain-infection-risk-with-lymphoma-drug <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and Drug Administration said Friday it has seen three cases of a serious brain infection among patients being treated with the lymphoma drug Adcetris, marketed by Seattle Genetics... Fri, 13 Jan 2012 13:23:15 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=48444606&headline=fda-panel-backs-seattle-genetics-lymphoma-drug-adcetris http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=48444606&headline=fda-panel-backs-seattle-genetics-lymphoma-drug-adcetris <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A federal advisory panel backed the approval of a Seattle Genetics Inc. (SGEN) experimental drug as a Hodgkin lymphoma treatment. </p> <p> The drug, which has a generic name of brentuximab... Thu, 14 Jul 2011 12:30:40 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=47998176&headline=reporters-notebook-cancer-meeting-emphasizes-cost-of-care http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=47998176&headline=reporters-notebook-cancer-meeting-emphasizes-cost-of-care <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- This year's meeting of the American Society of Clinical Oncology brought more updates than breakthroughs while it re-emphasized one of the biggest issues facing cancer care: continually rising costs... Wed, 08 Jun 2011 15:52:30 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=46123070&headline=us-regulator-court-order-freezes-insider-trading-case-assets http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=46123070&headline=us-regulator-court-order-freezes-insider-trading-case-assets <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> The U.S. Securities and Exchange Commission on Friday obtained a court order freezing assets controlled by a California man who allegedly made more than $800,000 by trading on inside information. </p> <p> The agency alleges Zizhong (James) Fan, a... Fri, 21 Jan 2011 13:34:24 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=45905186&headline=seattle-genetics-joins-with-pfizer-on-cancer-drug-technology http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=45905186&headline=seattle-genetics-joins-with-pfizer-on-cancer-drug-technology <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Seattle Genetics Inc. (SGEN) said drug giant Pfizer Inc. (PFE) has agreed to pay $8 million upfront and more than $200 million in potential milestone payments for the rights to use its antibody-drug conjugate technology. </p> <p> The biotechnology... Thu, 06 Jan 2011 08:28:59 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=44537865&headline=seattle-genetics-takeda-treatment-meets-primary-endpoint http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=44537865&headline=seattle-genetics-takeda-treatment-meets-primary-endpoint <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Seattle Genetics Inc. (SGEN) and its development partner said their experimental antibody-drug conjugate met its primary endpoint in a study. </p> <p> Seattle Genetics has had sharply higher revenue in recent quarters, helped by its antibody-drug... Mon, 27 Sep 2010 07:44:19 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=40844260&headline=seattle-genetics-glaxosmithkline-to-collaborate http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SGEN&article=40844260&headline=seattle-genetics-glaxosmithkline-to-collaborate <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Seattle Genetics Inc. (SGEN) will receive an upfront fee of $12 million and potential milestone payments of as much as $390 million under a collaboration agreement with GlaxoSmithKline PLC (GSK). </p> <p> The deal involves Seattle Genetics' antibody-drug... Mon, 21 Dec 2009 08:07:08 EST